It has been well-established that both GLP-1 and the RAS are involved in the pathogenesis and treatment of NAFLD; however, whether GLP-1 ameliorates NAFLD via its interaction with the RAS and the functional correlation between GLP-1 and the RAS during NAFLD remains unknown. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.